【摘要】 目的　探讨腹腔化疗在晚期卵巢上皮癌 (AEOC)不同组别中 (残留灶≤ 1cm组、>1cm组 )的预后意义。方法　对 336例 AEOC患者以残癌大小作为分层因素进行腹腔化疗作用的回顾性分析 ,L og- rank检验生存率差异 ,Cox比例风险模型进行预后多因素分析。结果　残癌≤ 1cm组有无腹腔化疗的中位生存期分别为 46个月和36个月 ,差异有显著性 (P=0 .0 0 6 5 ,χ2 =7.39) ;残癌 >1cm组的生存期差异无显著性。多因素结果显示 ,腹腔化疗是 AEOC患者的预后影响因素之一。结论　腹腔化疗明显提高了残癌≤ 1cm组的远期生存期 ,该结果有待于随机化研究证实。更多还原

【Abstract】 Objective To investigate the role of first-line intraperitoneal chemotherapy in the management of advanced epithelial ov arian cancer (AEOC).Methods From 1986 to 1997,336 patients with stage Ⅲ and stage Ⅳ ovarian cancer treated in our institute were retrospectiv ely reviewed, and the patients were divided into optimal and suboptimal groups a ccording to the residual disease after primary surgical cytoreduction.Re sults In the optimal group, there was a significant difference in survi val between patients with and without intraperitoneal chemotherapy, with an esti mated median survival of 46 months and 36 months,respectively ( P =0.0065, χ2 =7.39). Intraperitoneal chemotherapy was also identified as one of indepe ndent prognostic factors of survival by Cox stepwise regression analysis.Conclusion Intraperitoneal chemotherapy can significantly improve lon g-term survival of patients with optimal advanced epithelial ovarian cancer.更多还原